Solid Biosciences Inc

SLDBNASDAQ · USD
7.48USD-0.54 (-6.74%)
2310

Solid Biosciences Inc (SLDB) Implied Volatility Current

SLDB implied volatility is 126%. IV Rank is 17%, placing current premiums in the bottom of their 52-week range.

Read more

Tracking SLDB implied volatility helps you identify when options premiums on Solid Biosciences Inc are historically cheap or expensive, and where the best trades are hiding. Solid Biosciences Inc implied volatility reflects the market's expectation of future price movement: when SLDB IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Solid Biosciences Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For SLDB, tracking metrics like SLDB IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on SLDB signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.

to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where SLDB implied volatility sits today versus where it has been. Our scanner ranks Solid Biosciences Inc implied volatility against its historical range, surfaces extremes in SLDB IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Solid Biosciences Inc IV is rich or cheap — measure it, then act on it.

Implied Volatility

IV Rank
17.46%IV Rank
Low

IV is compressed vs the past year - options are relatively cheap, favoring buyers.

Implied Volatility (30d)126.44%

IV Rank17.46%

Historical Volatility (30d)65.40%

IV - HV+61.04%

As of September 23, 2026

Trade options with IV on your side

Track SLDB IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.

Start your 14-day free trial